Preliminary results for a phase 2 trial of the experimental compound olesoxime suggest it may preserve motor function in spinal muscular atrophy
posted on March 13, 2014 - 9:41am
Update (Feb. 2, 2015): Swiss pharmaceutical company Roche announced in a Jan. 16, 2015, press release, that it will acquire Trophos and continue development of olesoxime for SMA. "We will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who with live with this devastating condition as quickly as...
Reversing muscle damage caused by low SMN; nerve-muscle communication breakdown; phase 2 trial of olesoxime now fully enrolled
posted on September 27, 2011 - 4:35pm
Skeletal muscle damage reversed in SMA mice
In addition to muscle damage caused by the loss of motor neurons in the spinal cord, skeletal muscle degeneration in spinal muscular atrophy (SMA) also stems from low levels of the protein SMN in muscle fibers. Now a team of scientists from Germany and the United Kingdom reports that muscle damage caused by low SMN can be reversed with drugs.
Reports on research in amyotrophic lateral sclerosis, Duchenne muscular dystrophy, myotubular myopathy and spinal muscular atrophy
posted on August 12, 2010 - 11:33am
Duchenne muscular dystrophy
Acceleron Pharma announced Aug. 4 that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its experimental compound ACE031 for the treatment of Duchenne muscular dystrophy (DMD). ACE031 is designed to interfere with the actions of myostatin, a protein that inhibits muscle growth.